Robitaille Chantal, Dajczman Esther, Hirsch Andrew M, Small David, Ernst Pierre, Porubska Dana, Palayew Mark
Can Respir J. 2015 Jul-Aug;22(4):209-14. doi: 10.1155/2015/306720. Epub 2015 May 11.
Targeted spirometry screening for chronic obstructive pulmonary disease (COPD) has been studied in primary care and community settings. Limitations regarding availability and quality of testing remain. A targeted spirometry screening program was implemented within a presurgical screening (PSS) clinic to detect undiagnosed airways disease and identify patients with COPD/asthma in need of treatment optimization.
The present quality assurance study evaluated airflow obstruction detection rates and examined characteristics of patients identified through the targeted screening program.
The targeted spirometry screening program was implemented within the PSS clinic of a tertiary care university hospital. Current or ex-smokers with respiratory symptoms and patients with a history of COPD or asthma underwent prebronchodilator spirometry. History of airways disease and smoking status were obtained during the PSS assessment and confirmed through chart reviews.
After exclusions, the study sample included 449 current or ex-smokers. Abnormal spirometry results were found in 184 (41%) patients: 73 (16%) had mild, 93 (21%) had moderate and 18 (4%) had severe or very severe airflow obstruction. One hundred eighteen (26%) new cases of airflow obstruction suggestive of COPD were detected. One-half of these new cases had moderate or severe airflow obstruction. Only 34% of patients with abnormal spirometry results had reported a previous diagnosis of COPD. More than one-half of patients with abnormal spirometry results were current smokers.
Undiagnosed airflow obstruction was detected in a significant number of smokers and ex-smokers through a targeted screening program within a PSS clinic. These patients can be referred for early intervention and secondary preventive strategies.
在初级保健和社区环境中,已对慢性阻塞性肺疾病(COPD)的针对性肺量计筛查进行了研究。检测的可用性和质量方面仍存在局限性。在术前筛查(PSS)诊所实施了一项针对性肺量计筛查计划,以检测未确诊的气道疾病,并识别需要优化治疗的COPD/哮喘患者。
本质量保证研究评估了气流阻塞检测率,并检查了通过针对性筛查计划识别出的患者的特征。
在一家三级护理大学医院的PSS诊所实施了针对性肺量计筛查计划。有呼吸道症状的现吸烟者或既往吸烟者以及有COPD或哮喘病史的患者接受了支气管扩张剂前肺量计检查。在PSS评估期间获取气道疾病史和吸烟状况,并通过病历审查进行确认。
排除后,研究样本包括449名现吸烟者或既往吸烟者。184名(41%)患者的肺量计检查结果异常:73名(16%)有轻度气流阻塞,93名(21%)有中度气流阻塞,18名(4%)有重度或极重度气流阻塞。检测到118例(26%)提示COPD的气流阻塞新病例。这些新病例中有一半患有中度或重度气流阻塞。肺量计检查结果异常的患者中,只有34%曾报告被诊断为COPD。肺量计检查结果异常的患者中,超过一半是现吸烟者。
通过PSS诊所内的针对性筛查计划,在大量吸烟者和既往吸烟者中检测到了未确诊的气流阻塞。这些患者可被转诊接受早期干预和二级预防策略。